Drugs Made In America Acquisition Corp. (DMAAU) Liabilities and Shareholders Equity (2024 - 2025)

Drugs Made In America Acquisition (DMAAU) has 2 years of Liabilities and Shareholders Equity data on file, last reported at $239.9 million in Q4 2025.

• Quarterly Liabilities and Shareholders Equity rose 43456.35% year-over-year to $239.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $945.6 million (changed N/A YoY) and the FY2025 annual result came in at $239.9 million, up 43456.35% from the prior year.
• Liabilities and Shareholders Equity climbed to $239.9 million in Q4 2025, from $237.6 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $239.9 million in Q4 2025 to a low of $550824.0 in Q4 2024.